



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

Sm

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/666,696	09/19/2003	Ulrich Feige	A-527H	8548
7590	08/03/2004		EXAMINER	
US Patent Operations/[TJG] Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, CA 91320-1799			WESSENDORF, TERESA D	
			ART UNIT	PAPER NUMBER
			1639	
DATE MAILED: 08/03/2004				

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/666,696	FEIGE ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	T. D. Wessendorf	1639	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 16 June 2004.
- 2a) This action is FINAL.      2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-7,22-27 and 43-51 is/are pending in the application.
- 4a) Of the above claim(s) 22-27 and 43-51 is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1-7 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All    b) Some \* c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_.
- 4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: \_\_\_\_\_.

**DETAILED ACTION**

***Election/Restrictions***

Applicant's election of Group I claims 1-7 in the reply filed on 6/16/04 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

The species restriction is withdrawn with the amendments to the claims of a random peptide sequences.

Claims 22-27 and 43-51 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 6/16/04.

***Status of Claims***

Claims 1-7, 22-27 and 43-51 are pending in the application.

Claims 22-27 and 43-51 are withdrawn from consideration as being drawn to non-elected invention.

Claims 8-21 and 28-42 have been cancelled in the Preliminary Amendment of 9/19/03.

[Claims 52-62, the status of which were not provided in the Preliminary Amendment, are cancelled in view of the statement

Art Unit: 1639

that the claims in Preliminary Amendment replaced all the prior versions of the claims.]

Claims 1-7 are under examination.

***Specification***

The abstract of the disclosure is objected to because it is too long. Also, because of the used of the phraseology often used in patent claims e.g., "comprising". Correction is required. See MPEP § 608.01(b) .

Applicant is reminded of the proper language and format for an abstract of the disclosure.

The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words. It is important that the abstract not exceed 150 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

The disclosure is objected to because of the following informalities:

The status of the applications recited at page 1 has not been provided.

Art Unit: 1639

Appropriate correction is required.

The attempt to incorporate subject matter into this application by reference to e.g., Sparks et al. (1996), Proc. Natl. Acad. Sci. 93: 1540-4, is improper because it is a publication.

The incorporation of essential material in the specification (paragraph bridging pages 30-31) by reference to the numerous World Patents e.g., WO 95/14714 and 97/08203 and publications is improper. Applicant is required to amend the disclosure to include the material incorporated by reference. The amendment must be accompanied by an affidavit or declaration executed by the applicant, or a practitioner representing the applicant, stating that the amendatory material consists of the same material incorporated by reference in the referencing application. See *In re Hawkins*, 486 F.2d 569, 179 USPQ 157 (CCPA 1973); *In re Hawkins*, 486 F.2d 579, 179 USPQ 163 (CCPA 1973); and *In re Hawkins*, 486 F.2d 577, 179 USPQ 167 (CCPA 1973).

The specification has not been checked to the extent necessary to determine the presence of all possible minor errors (grammatical, typographical and idiomatic). Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-7 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

A). The as-filed specification fails to provide a written description support for the now claimed, "randomized Ang-2 binding peptide" and "...neither X1 nor X2 is a native protein." The as-filed specification does not provide the description as to the X variables not being a native protein. MPEP 714.02 recites that applicants specifically point out where in the specification support for the new claimed limitations appear.

B). The specification fails to provide an adequate written description of a randomized Ang-2 binding peptide molecule. The specification does not teach any peptide sequence for Ang-2 binding sequences, let alone, its randomization. There is no

description as to the kind of amino acids, the location, the number of residues that can be randomized in said Ang-2 binding molecule. More importantly, the linking of said random peptide to the Fc domain. The specification provides a single statement or mention Ang-2. Other than this passing remark, no native sequence of said Ang-2 binding molecule or fragments is described, if any has been randomized. To provide adequate written description for any type of Ang-2 binding molecule linked to an Fc region by any linker, evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying

characteristics of the genus. A "written description of an invention involving a chemical genus, like a description of a chemical species, requires a precise definition, such as by structure, formula [or] chemical name of the claimed subject matter sufficient to distinguish it from other materials".

University of California v. Eli Lilly and Co., 43 USPQ 2d 1398, 1405 (1997), quoting Fiers V. Revel, 25 USPQ 2d 1601m 16106 (Fed. Cir. 1993). See also University of Rochester v. G.D. Searle & Co., 68 USPQ2d 1424 (DC WNY 2003).

***Claim Rejections - 35 USC § 112, second paragraph***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 is indefinite as to the recitation that X2 nor X2 is not a native protein. The preceding claim recites these variables as peptide. Does the native protein means that the peptides are non-naturally occurring amino acids?

It is suggested that applicants provide for the complete name for the acronym Ang-2.

***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Art Unit: 1639

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-7 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-7 of copending Application No. 09/563286 ('286 application). Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claimed species is encompassed or included by the broad or generic claimed "randomized peptides" of the '286 application.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cerretti et al (WO 00/75323).

Cerretti et al discloses at page 6, lines 10-15 a Tek multimer including dimers, trimers or higher multimers covalently or non-covalently linked by peptide linkers to a Fc domain. Cerretti further discloses at page 8, line 4 up to page 9 line 6 Tek multimer variants that has one to ten amino acid sequence variations by deletions, substitutions or insertions compared to the native Tek. Furthermore, Cerretti discloses at page 14, lines 15-24 antibodies immunoreactive with the polypeptide. The Tek antibodies are prepared by phage display, inter alia. In Example 4, page 22 Cerretti describes the binding of the Tek polypeptide to the different Ang ligands, e.g., Ang-2 ligand. Cerretti discloses at page 9, lines 35-36 disclose that due to the degeneracy of genetic code, there can be considerable variation in nucleotide sequences encoding the same amino acid. Cerretti does not disclose a fusion protein of Fc wherein the Ang-2 binding is randomized. However, such randomization would have been obvious to one having ordinary skill in the art in view of the teachings of Cerretti of variants of the Ang-2 binding peptide i.e., Tek polypeptide, wherein one to ten amino acids are varied in a

random manner. Such variations in the amino acids would suggest random amino acids. One having ordinary skill in the art would be motivated to randomized portions of the Ang-2 binding molecule (i.e., Tek). Randomization produces a diverse or more variants that leads to the discovery of lead compounds with better pharmacological effect.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to T. D. Wessendorf whose telephone number is (703) 308-3967. The examiner can normally be reached on Flexitime.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on (703) 306-3217. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-7924 for regular communications and (703) 308-7924 for After Final communications.

Art Unit: 1639

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

T.D. W

T. D. Wessendorf  
Primary Examiner  
Art Unit 1639

tdw  
July 23, 2004